Hummingbird Bioscience picks Jan Moller Mikkelsen as Board Chairman

Hummingbird Bioscience Holdings, a Singapore and US-based innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, has announced the appointment of Jan Moller Mikkelsen as Chairman of its Board of Directors. Mikkelsen currently serves as President, Chief Executive Officer and Board member of Ascendis Pharma, a pharmaceutical company he founded in 2007. He was previously President and CEO of LifeCycle Pharma, President of the Pharmaceutical Division of Maxygen, Inc., as well as co-founder of ProFound Pharma where he also served as co-CEO. Prior to that, Mikkelsen held various positions at Novo Nordisk, a global healthcare company, including Vice President of Protein Discovery.